The active patients with RA had a higher prevalence of MAFLD than those in remission (according to CDAI: 23.1 vs. 12.0%, Figure 1D; DAS28-CRP: 23.6 vs. 14.6%, Figure 1E; SDAI: 22.7 vs. 13.9%, Figure 1F and DAS28-ESR: 22.6 vs. 14.1%, Figure 1G), whereas there was no significant difference in MAFLD prevalence among patients with RA with low, moderate, and high disease activity (Figures 1J–M), between treatment naïve and treated patients with RA (Figure 1H), and among different disease durations (Figure 1I). Here, CRP is linked to rheumatoid arthritis.